Business Wire

WA-SPIE

30.9.2021 11:05:11 CEST | Business Wire | Press release

Share
SPIE and the University of Birmingham Establish $800,000 Photonics-focused Education Fund

SPIE, the international society for optics and photonics , and the University of Birmingham have announced the establishment of the SPIE Optics and Photonics Champion Academy fund. The new endowment was announced this morning, during SPIE Photonex + Vacuum Technologies in Glasgow, Scotland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005066/en/

The $400,000 gift from the SPIE Endowment Matching Program will be matched 100% by the university, and the $800,000 fund will create and support the SPIE Optics and Photonics Champion Academy. The cohort-focused program will engage in areas of public interest in the fields of quantum technology and biomedical imaging and data sciences: one of the first projects will address pandemics. The program will be led by Professor and Principal Investigator of the UK Quantum Technology Hub Sensors and Timing Kai Bongs , and Professor of Computational Life Sciences Iain Styles .

The SPIE Optics and Photonics Champion Academy will support University of Birmingham students in a variety of ways which include expanding cross-disciplinary educational opportunities in optics and photonics; offering students hands-on support and training to become influential science communicators and advocates of optics and photonics; and by utilizing a range of stipends, awards, and activity grants, which will be supplemented with professional development and mentoring opportunities from the university’s academic leaders as well as from external experts.

The program will focus particularly on students in underrepresented groups, early-career researchers, and PhD students in order to establish and build a broad, diverse, and inclusive network of science advocates, especially in the area of optics and photonics.

“We are delighted to be able to work with SPIE to launch this unique Academy at the University of Birmingham,” said Professor Bongs. “This initiative will help to accelerate the growth of optics and photonics expertise, which will have great impact far beyond the university. Our hope is to not only encourage this learning, but to also create awareness of the huge importance of this subject area in tackling real-world problems.”

“By equipping early-career optics and photonics researchers and PhD students with skills in advanced data analysis, we will help to accelerate the translation of these exciting technologies from the laboratory to their adoption in real-world applications,” added Professor Styles. “Our SPIE Champions will be able to work with experts in diverse application areas such as healthcare and climate monitoring to develop end-to-end optics-based solutions with integrated analytics for some of our most pressing challenges.”

“By offering direct, experiential training in quantum technology and biomedical imaging as well as highlighting various career options in the field, the SPIE Optics and Photonics Champion Academy will develop a natural pipeline of future professional scientists and engineers in these fields,” noted SPIE President David Andrews . “And by encouraging students to actively raise awareness of the impact of optics and photonics to their contemporaries, peers, and younger colleagues, the program will be creating visible, engaged role models for future generations.”

The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics, and to date has given more than $3.4 million in matching gifts, resulting in more than $9 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.

About SPIE

SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye